Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules.

Autor:	Xing L; Department of Pathology, Hebei Medical University, Shijiazhuang, China. xinglingxiao@hotmail.com fjiang@som.umaryland.edu., Su J; Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland., Guarnera MA; Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland., Zhang H; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland., Cai L; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland., Zhou R; Nevada Cancer Center, Las Vegas, Nevada., Stass SA; Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland., Jiang F; Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland. xinglingxiao@hotmail.com fjiang@som.umaryland.edu.
Jazyk:	angličtina
Zdroj:	Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Jan 15; Vol. 21 (2), pp. 484-9.
DOI:	10.1158/1078-0432.CCR-14-1873
Abstrakt:	Purpose: The early detection of lung cancer in heavy smokers by low-dose CT (LDCT) can reduce the mortality. However, LDCT screening increases the number of indeterminate solitary pulmonary nodules (SPN) in asymptomatic individuals, leading to overdiagnosis. Making a definitive preoperative diagnosis of malignant SPNs has been a clinical challenge. We have demonstrated that sputum miRNAs could provide potential biomarkers for lung cancer. Here, we aimed to develop sputum miRNA biomarkers for diagnosis of malignant SPNs. Experimental Design: Using quantitative RT-PCR, we evaluated expressions of 13 sputum miRNAs, previously identified sputum miRNA signatures of lung cancer, in a training set of 122 patients with either malignant (n = 60) or benign SPNs (n = 62) to define a panel of biomarkers. We then validated the biomarker panel in an internal testing set of 136 patients with either malignant (n = 67) or benign SPNs (n = 69), and an external testing cohort of 155 patients with either malignant (n = 76) or benign SPNs (n = 79). Results: In the training set, a panel of three miRNA biomarkers (miRs21, 31, and 210) was developed, producing 82.93% sensitivity and 87.84% specificity for identifying malignant SPNs. The sensitivity and specificity of the biomarkers in the two independent testing cohorts were 82.09% and 88.41%, 80.52% and 86.08%, respectively, confirming the diagnostic value. Conclusions: Sputum miRNA biomarkers may improve LDCT screening for lung cancer in heavy smokers by preoperatively diagnosing malignant SPNs. Nevertheless, a prospective study in a large population to validate the biomarkers is needed. (©2015 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu